Who is sponsoring NCT02402374?

NCT02402374 is sponsored by Regen Lab SA.

What drugs are being tested in NCT02402374?

Interventions in NCT02402374: Autologous platelet rich plasma gel, Placebo.

What condition does NCT02402374 study?

NCT02402374 studies Diabetic Foot Ulcers.

Is NCT02402374 still recruiting?

NCT02402374 is currently status unknown. Last updated 8 October 2020.

Last reviewed 2020-10-08 · How we verify

NCT02402374

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluate the Safety and Efficacy of RegenKit Autologous PRP Gel for the Treatment of Diabetic Foot Ulcer

Status unknown NA Last updated 8 October 2020

What this trial tests

NA trial testing Autologous platelet rich plasma gel in Diabetic Foot Ulcers in 192 participants. Status unknown.

Timeline

12 April 2018

Primary endpoint
30 October 2020

30 December 2020

Quick facts

Lead sponsor	Regen Lab SA
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	192
Start date	12 April 2018
Primary completion	30 October 2020
Estimated completion	30 December 2020
Sites	1 location across United States

Drugs / interventions tested

Autologous platelet rich plasma gel
Placebo

Conditions studied

Diabetic Foot Ulcers — all drugs for Diabetic Foot Ulcers →

Sponsor

Regen Lab SA

Who can join

Adults 18 to 95, any sex, with Diabetic Foot Ulcers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Autologous platelet-rich plasma (PRP) gel was reported to have very good outcomes in the treatment of foot ulcers in pilot studies and retrospective uncontrolled trials. Therefore, a larger randomized, placebo-controlled clinical trial will be useful to determine whether platelet-rich plasma is safe and effective for the treatment of diabetic foot ulcers (DFU).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetic Foot Ulcers

Currently open trials in the same condition.

NCT06189638 — Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers · Phase 2 · active not recruiting

Other Regen Lab SA trials

Trials by the same sponsor.

NCT02591355 — Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment · NA · completed
NCT03328728 — Cellular Matrix Device for the Treatment of Mild to Moderate Knee Osteoarthritis · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02402374 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Regen Lab SA
Last refreshed: 8 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02402374.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing